Statin use is associated with a reduced incidence of colorectal adenomatous polyps

International Journal of Colorectal Disease

Volumn 28, Issue 4, 2013, Pages 469-476

  Broughton, Thomas ^b   Sington, Jamie ^a   Beales, Ian L P ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Aspirin; Chemoprevention; Colorectal adenocarcinoma; Colorectal adenomas; Hydroxymethylglutaryl CoA reductase inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL AFFECTING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; SIMVASTATIN;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; COLON POLYPOSIS; COLONOSCOPY; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECTUM ADENOMA; RISK REDUCTION; TREATMENT DURATION;

ADENOMATOUS POLYPS; ASPIRIN; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INTESTINAL POLYPS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84877876798     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-012-1601-9     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108
2. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873-874
3. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071-1080
4. Asano TK, McLeod RS (2004) Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev (2):CD004079
5. Feleszko W, Jakobisiak M (2000) Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 6(3):1198-1199
6. Yasuda Y, Shimizu M, Shirakami Y, Sakai H, Kubota M, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H (2010) Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 101(7):1701-1707
7. Yasui Y, Suzuki R, Miyamoto S, Tsukamoto T, Sugie S, Kohno H, Tanaka T (2007) A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. Int J Cancer 121(10):2331-2339
8. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G (2005) Statins and the risk of colorectal cancer. N Engl J Med 352(21):2184-2192
9. Taylor ML, Wells BJ, Smolak MJ (2008) Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev 17(3):259-268
10. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17(1):27-36
11. Shadman M, Newcomb PA, Hampton JM, Wernli KJ, Trentham-Dietz A (2009) Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. World J Gastroenterol 15(19):2336-2339
12. Lipkin SM, Chao EC, Moreno V, Rozek LS, Rennert H, Pinchev M, Dizon D, Rennert G, Kopelovich L, Gruber SB (2010) Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) 3(5):597-603
13. Hachem C, Morgan R, Johnson M, Kuebeler M, El-Serag H (2009) Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am J Gastroenterol 104(5):1241-1248
14. Broughton T, Sington J, Beales IL (2012) Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case-control study. BMC Gastroenterol 12:36
15. Singh H, Mahmud SM, Turner D, Xue L, Demers AA, Bernstein CN (2009) Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol 20 104(12):3015-3023
16. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J (2010) Incidence of cancer and statin usage - record linkage study. Int J Cancer 126(1):279-284
17. Coogan PF, Smith J, Rosenberg L (2007) Statin use and risk of colorectal cancer. J Natl Cancer Inst 99(1):32-40
18. Kaye JA, Jick H (2004) Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90(3):635-637
19. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF (2007) Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 133(2):393-402
20. Vinogradova Y, Coupland C, Hippisley-Cox J (2011) Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 11:409
21. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71(5):1763-1771
22. Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59(11):1572-1585
23. Boudreau DM, Yu O, Johnson J (2010) Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 9(4):603-621
24. Ogunwobi OO, Beales IL (2008) Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 103(4):825-837
25. Hill MJ, Morson BC, Bussey HJ (1978) Aetiology of adenoma - carcinoma sequence in large bowel. Lancet 1(8058):245-247
26. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J (2010) Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375(9726):1624-1633
27. Wu JS, Fazio VW (2000) Colon cancer. Dis Colon Rectum 43(11):1473-1486
28. Teraoka N, Mutoh M, Takasu S, Ueno T, Yamamoto M, Sugimura T, Wakabayashi K (2011) Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor. Cancer Prev Res (Phila) 4(3):445-453
29. Siddiqui AA, Nazario H, Mahgoub A, Pandove S, Cipher D, Spechler SJ (2009) The long-term use of statins is associated with a decreased incidence of adenomatous colon polyps. Digestion 79(1):17-22
30. Parker-Ray N, Barakat J, Roy PK, White RE, Schrader RM, Hoffman RM (2010) Statin use does not prevent recurrent adenomatous polyp formation in a VA population. Indian J Gastroenterol 29(3):106-1
31. Siddiqui A, Nazario HE, Patel M, Mahgoub A, Spechler SJ (2009) Reduction in low-density lipoprotein cholesterol levels during statin therapy is associated with a reduced incidence of advanced colon polyps. Am J Med Sci 338(5):378-381
32. Wei JT, Mott LA, Baron JA, Sandler RS (2005) Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 14(4):1026-1027
33. Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG (2010) Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 3(5):588-596
34. Morgan C, Lunt M, Bunn D, Scott DG, Symmons DP (2007) Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis. Rheumatology (Oxford) 46(12):1819-1823
35. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP et al (2010) Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59(5):666-689
36. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV (2006) Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 66(14):7370-7377
37. Neale RE, Doecke JD, Pandeya N, Sadeghi S, Green AC, Webb PM, Whiteman DC (2009) Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? Br J Cancer 100(5):795-798
38. Cerda SR, Wilkinson J 4th, Broitman SA (1995) Regulation of cholesterol synthesis in four colonic adenocarcinoma cell lines. Lipids 30(12):1083-1092
39. Minoo P, Zlobec I, Peterson M, Terracciano L, Lugli A (2010) Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol 37(3):707-718
40. Lee JE, Baba Y, Ng K, Giovannucci E, Fuchs C, Ogino S, Chan AT (2011) Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila) 4(11):1808-1815
41. Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK (2011) Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 103(8):674-688
42. Jalving M, Koornstra JJ, De Jong S, De Vries EG, Kleibeuker JH (2005) Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment Pharmacol Ther 21(4):321-329
43. Giouleme O, Diamantidis MD, Katsaros MG (2011) Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J Gastroenterol 17(4):444-448
44. Chan AO, Jim MH, Lam KF, Morris JS, Siu DC, Tong T, Ng FH, Wong SY, Hui WM, Chan CK et al (2007) Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 298(12):1412-1419
45. Siddiqui A, Pena Sahdala HN, Nazario HE, Mahgoub A, Patel M, Cipher D, Spechler S (2009) Obesity is associated with an increased prevalence of advanced adenomatous colon polyps in a male veteran population. Dig Dis Sci 54(7):1560-1564
46. Kitahara CM, Berrington de Gonzales A, Freedman N, Huxley R, Mok Y, Jee SH, Samet JM (2011) Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 29(12):1592-1598
47. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3(11):1451-1461
48. Hippisley-Cox J, Coupland C (2010) Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340:c2197
49. Yang Z, Xiao H, Jin H, Koo PT, Tsang DJ, Yang CS (2010) Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. Int J Cancer 126(4):852-863